Gland Pharma Ltd - Margins Impacted by Cenexi Business; Maintain HOLD
GLAND (Ex-Cenexi) registered a muted revenue growth of 5.1% YoY due to the annual shutdown of planned maintenance, maintaining EBITDA margins of...
141 Views
Gland Pharma Ltd - Margins Impacted by Subsidiary; Maintain HOLD
GLAND (Ex-Cenexi) registered a revenue growth of 14.2% YoY, maintaining EBITDA margins of ~29%, which is in line with preceding quarters on a YoY...
148 Views
Gland Pharma Ltd - Operating Losses in Subsidiary; Maintain HOLD
GLAND (Ex-Cenexi) registered consistent revenue growth of 49.5% YoY, maintaining EBITDA margins of ~34%, which is in line with preceding quarters.
177 Views
Gland Pharma Ltd (GLAND IN): Business Recovery Seems To Be Overlooked by Mr. Market
Gland Pharma reports steady growth in base business and is confident to end FY24 on high note. While the US will remain main growth driver, the...
334 Views
Gland Pharma - Performance in Revival Mode; Valuation Attractive
Gland Pharma (GLAND) has seen an encouraging revival in its business performance in 9MFY24 after a weak FY23. The revival in sales in the...
361 Views